Huaxia Eye(301267.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Huaxia Eye
301267.SZ
Huaxia Eye Hospital Group Co.,Ltd. operates an ophthalmic medical chain in China and internationally. The company provides general ophthalmology diagnosis and treatment services for patients with ophthalmic diseases; and myopia prevention and intervention work to the public. It offers services in the areas of cataract, refraction, fundus, strabismus and amblyopia, pediatric ophthalmology, ocular surface, glaucoma, orbital and ocular tumors, and ocular trauma.
188.65 B
301267.SZMarket value -Rank by Market Cap -/-

Financial Score

23/01/2026 Update
C
Health Care FacilitiesIndustry
Industry Ranking4/9
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.48%B
    • Profit Margin10.72%B
    • Gross Margin45.18%B
  • Growth ScoreC
    • Revenue YoY0.60%C
    • Net Profit YoY-16.62%D
    • Total Assets YoY1.29%C
    • Net Assets YoY2.83%C
  • Cash ScoreC
    • Cash Flow Margin932.64%B
    • OCF YoY0.60%C
  • Operating ScoreC
    • Turnover0.51C
  • Debt ScoreB
    • Gearing Ratio23.95%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The first Guangdong-Hong Kong-Macao Medical Technology Innovation and Transformation Summit was held in Hong Kong to build a communication platform for the three regions and promote the clinical transformation of cutting-edge tumor therapies

    The first Guangdong-Hong Kong-Macao Medical Technology Innovation and Transformation Summit was held in Hong Kong, focusing on immunology, genetics, and new therapies for cancer. The conference gathered over 150 experts to discuss medical technology innovation and clinical transformation. The organizers emphasized the importance of regional medical collaboration and are committed to promoting high-quality cross-border medical development. Several renowned scholars shared cutting-edge research findings and discussed challenges such as research funding and insurance coverage, aiming to make advanced medical care accessible to patients

    Stheadline·
    Stheadline·

    China ranks among the top in the world for the effective number of artificial intelligence patents

    The Deputy Director of the National Intellectual Property Administration, Rui Wenbiao, stated at a press conference held by the State Council Information Office that the number of high-value invention patents in China has reached 2.292 million, with the effective number of artificial intelligence patents ranking among the top globally. The growth rate of effective invention patents in fields such as information technology management methods, computer technology, and medical technology is the fastest

    36Kr·
    US
    MCHI
    -0.06%
    36Kr·
    US
    MCHI
    -0.06%

    Build "Health Stations"! 9 departments issued documents to promote the high-quality development of the pharmaceutical retail industry

    The Ministry of Commerce and 8 other departments jointly issued opinions to promote the high-quality development of the pharmaceutical retail industry, proposing 18 measures aimed at transforming pharmacies into "health service hubs." The measures include enhancing pharmaceutical service capabilities, optimizing the purchasing experience, participating in centralized procurement, and building a payment guarantee system, further strengthening the health service functions of retail pharmacies to better meet the medical and health needs of the people

    Wallstreetcn·
    US
    MCHI
    -0.06%
    Wallstreetcn·
    US
    MCHI
    -0.06%

    Certain A Shares of Huaxia Eye Hospital Group Co.,Ltd. are subject to a Lock-Up Agreement Ending on 7-NOV-2025.

    Certain A Shares of Huaxia Eye Hospital Group Co., Ltd. are under a Lock-Up Agreement until 7-NOV-2025, lasting 1109 days from 25-OCT-2022. Key stakeholders, including the actual controller and various shareholders, have committed to not transferring their shares for specified periods post-listing. If share prices fall below the issuance price for consecutive trading days, the lock-up may extend. After expiration, they can only transfer 25% of their shares annually while in office.

    marketscreener·
    SZ
    301267
    +1.36%
    marketscreener·
    SZ
    301267
    +1.36%

    30 stocks will face lifting of restrictions next week

    Next week, 30 stocks will be unlocked, with a total unlocked market value of 20.322 billion yuan. Huaxia Eye will unlock 511 million shares, with a market value of 9.993 billion yuan, the highest unlock scale. Yunding Tech will unlock 153 million shares, with a market value of 1.74 billion yuan, the second highest unlock scale. Huaxia Eye has the highest unlock ratio, reaching 60.85%

    Zhitong·
    SZ
    301267
    +1.36%
    SZ
    000409
    +1.76%
    Zhitong·
    SZ
    301267
    +1.36%
    SZ
    000409
    +1.76%
    © 2026 Longbridge｜Disclaimer